Sign in to view content

1-Year Results of a Phase 2 Pharmacodynamic Study: Subretinal Delivery of Investigational Gene Therapy ABBV-RGX-314 for Neovascular AMD

Robert L. Avery, MD

Video
Published 2025

Related

Safety and Efficacy of Risuteganib in Intermediate Nonexudative AMD: First Time Results From a Phase 2 Study
Peter K. Kaiser, MD FASRS
Annual Meeting Talks
2019
Efficacy and Safety of Multiwavelength Photobiomodulation in Dry Age-Related Macular Degeneration Using the LumiThera Valeda System (LIGHTSITE III Interim Analysis)
Richard B. Rosen, MD, DSc(Hon), FACS, FASRS, FARVO
Updates from the Field
2022
Staring a Clinical Trials Program
David A. Eichenbaum, MD, FASRS
Updates from the Field
2019

Category: AMD-Neovascular

See more